Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: The Northwestern University experience

Transplantation

Volumn 86, Issue 8, 2008, Pages 1052-1059

  Tambur, Anat R ^a   Leventhal, Joseph ^a   Kaufman, Dixon B ^a   Friedewald, John ^a   Miller, Joshua ^a   Abecassis, Michael M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CPRA; Highly sensitized; Transplantability

Indexed keywords

HLA ANTIBODY; PANEL REACTIVE ANTIBODY; PRONASE; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ALGORITHM; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; ORGAN DONOR; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; CASE REPORT; COMMUNICABLE DISEASE; COMPARATIVE STUDY; COMPUTER INTERFACE; DECISION TREE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; UNITED STATES; UNIVERSITY;

ADULT; ALGORITHMS; ANTIBODY SPECIFICITY; CHICAGO; COMMUNICABLE DISEASES; DECISION TREES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GUIDELINE ADHERENCE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNIZATION; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNIVERSITIES; USER-COMPUTER INTERFACE;

EID: 55949110219     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181874b06     Document Type: Article

References (20)

1. OPTN/STRT report. Available at: http://wwwoptnorg/AR2006/ defaulthtm 2006.
2. Zachary AA, Braun WE. Calculation ofapredictive value for transplantation. Transplantation 1985; 39: 316.
3. Zachary AA, Steinberg AG. Statistical analysis and applications of HLA population data. In: Rose NR, de Marcario EC, Folds JD, et al., eds. Manual of clinical laboratory immunology, [ed. 5] Washington, DC, ASM Press, 1997, p 132.
4. Bray RA, Lebeck LK, Gebel HM. The flow cytometric crossmatch. Dual-color analysis of T cell and B cell reactivities. Transplantation 1989; 48: 834.
5. Lobo PI, Spencer CE, Stevenson WC, et al. The use of pronase-digested human leukocytes to improve specificity of the flow cytometric cross-match. Transpl Int 1995; 8: 472.
6. Cecka JM, Zhang Q, Reed EF. Preformed cytotoxic antibodies in potential allograft recipients: Recent data. Hum Immunol 2005; 66: 343.
7. Leffell MS, Montgomery RA, Zachary AA. The changing role of antibody testing in transplantation. Clin Transpl 2005: 259.
8. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs risk. Am J Transplant 2003; 3: 1488.
9. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6: 2307.
10. Bielmann D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626.
11. Goodman RS, Taylor CJ, O'Rourke CM, et al. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation. Transplantation 2006; 81: 1331.
12. Zangwill SD, Ellis TM, Zlotocha J, et al. The virtual crossmatch - A screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006; 10: 38.
13. Vaidya S, Partlow D, Susskind B, et al. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006; 82: 1524.
14. Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807.
15. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027.
16. Vasilescu ER, Ho EK, Colovai AI, et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 2006; 67: 597.
17. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857.
18. Iniotaki-Theodoraki AG, Boletis JN, Trigas G, et al. Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplantation period. Transplantation 2003; 75: 1601.
19. Arnold ML, Pei R, Spriewald B, et al. Anti-HLA class II antibodies in kidney retransplant patients. Tissue Antigens 2005; 65: 370.
20. Tambur AR, Buckingham M, McDonald L, et al. Development of donor-specific and non-donor specific HLA-DP antibodies post transplant: The role of epitope sharing and epitope matching. In: Clinical Transplants 2006 [chap. 33]. UCLA Tissue Typing Laboratory, pp. 83-86.